nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—ADRA1B—vas deferens—urinary bladder cancer	0.0829	0.362	CbGeAlD
Pergolide—HTR2A—urine—urinary bladder cancer	0.00749	0.0327	CbGeAlD
Pergolide—ADRA1D—prostate gland—urinary bladder cancer	0.00724	0.0316	CbGeAlD
Pergolide—CYP3A4—urine—urinary bladder cancer	0.00693	0.0303	CbGeAlD
Pergolide—CYP2D6—urine—urinary bladder cancer	0.00682	0.0298	CbGeAlD
Pergolide—ADRA1D—epithelium—urinary bladder cancer	0.00532	0.0232	CbGeAlD
Pergolide—ADRA1B—renal system—urinary bladder cancer	0.00504	0.022	CbGeAlD
Pergolide—DRD5—female reproductive system—urinary bladder cancer	0.00493	0.0215	CbGeAlD
Pergolide—ADRA1D—urethra—urinary bladder cancer	0.00485	0.0212	CbGeAlD
Pergolide—ADRA1A—prostate gland—urinary bladder cancer	0.00416	0.0182	CbGeAlD
Pergolide—KCNH2—prostate gland—urinary bladder cancer	0.00402	0.0175	CbGeAlD
Pergolide—ADRA2C—prostate gland—urinary bladder cancer	0.00396	0.0173	CbGeAlD
Pergolide—ADRA1D—female reproductive system—urinary bladder cancer	0.00395	0.0173	CbGeAlD
Pergolide—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00356	0.0156	CbGeAlD
Pergolide—KCNH2—seminal vesicle—urinary bladder cancer	0.0034	0.0148	CbGeAlD
Pergolide—ADRA2C—seminal vesicle—urinary bladder cancer	0.00335	0.0146	CbGeAlD
Pergolide—ADRA2A—prostate gland—urinary bladder cancer	0.00316	0.0138	CbGeAlD
Pergolide—HTR1A—renal system—urinary bladder cancer	0.00307	0.0134	CbGeAlD
Pergolide—ADRA1A—epithelium—urinary bladder cancer	0.00306	0.0133	CbGeAlD
Pergolide—HTR1B—female reproductive system—urinary bladder cancer	0.00305	0.0133	CbGeAlD
Pergolide—HTR1D—female reproductive system—urinary bladder cancer	0.00295	0.0129	CbGeAlD
Pergolide—HTR2C—female reproductive system—urinary bladder cancer	0.00293	0.0128	CbGeAlD
Pergolide—ADRA1A—renal system—urinary bladder cancer	0.00283	0.0124	CbGeAlD
Pergolide—HTR2B—female reproductive system—urinary bladder cancer	0.00275	0.012	CbGeAlD
Pergolide—KCNH2—renal system—urinary bladder cancer	0.00274	0.012	CbGeAlD
Pergolide—ADRA2C—renal system—urinary bladder cancer	0.0027	0.0118	CbGeAlD
Pergolide—KCNH2—urethra—urinary bladder cancer	0.00269	0.0117	CbGeAlD
Pergolide—ADRA2A—seminal vesicle—urinary bladder cancer	0.00267	0.0117	CbGeAlD
Pergolide—ADRA2C—urethra—urinary bladder cancer	0.00265	0.0116	CbGeAlD
Pergolide—HTR2B—vagina—urinary bladder cancer	0.00249	0.0109	CbGeAlD
Pergolide—KCNH2—female reproductive system—urinary bladder cancer	0.00219	0.00958	CbGeAlD
Pergolide—ADRA2A—urethra—urinary bladder cancer	0.00212	0.00925	CbGeAlD
Pergolide—KCNH2—vagina—urinary bladder cancer	0.00198	0.00866	CbGeAlD
Pergolide—HTR2A—epithelium—urinary bladder cancer	0.00198	0.00863	CbGeAlD
Pergolide—ADRA2C—vagina—urinary bladder cancer	0.00196	0.00854	CbGeAlD
Pergolide—HTR2A—smooth muscle tissue—urinary bladder cancer	0.0019	0.00831	CbGeAlD
Pergolide—HTR2A—renal system—urinary bladder cancer	0.00183	0.008	CbGeAlD
Pergolide—ADRA2A—female reproductive system—urinary bladder cancer	0.00173	0.00754	CbGeAlD
Pergolide—CYP3A4—renal system—urinary bladder cancer	0.0017	0.00741	CbGeAlD
Pergolide—CYP2D6—renal system—urinary bladder cancer	0.00167	0.00729	CbGeAlD
Pergolide—HTR2B—lymph node—urinary bladder cancer	0.00161	0.00702	CbGeAlD
Pergolide—ADRA2A—vagina—urinary bladder cancer	0.00156	0.00682	CbGeAlD
Pergolide—HTR2A—female reproductive system—urinary bladder cancer	0.00147	0.00641	CbGeAlD
Pergolide—CYP3A4—female reproductive system—urinary bladder cancer	0.00136	0.00593	CbGeAlD
Pergolide—CYP2D6—female reproductive system—urinary bladder cancer	0.00134	0.00584	CbGeAlD
Pergolide—HTR2A—vagina—urinary bladder cancer	0.00133	0.0058	CbGeAlD
Pergolide—KCNH2—lymph node—urinary bladder cancer	0.00128	0.0056	CbGeAlD
Pergolide—ADRA2C—lymph node—urinary bladder cancer	0.00127	0.00553	CbGeAlD
Pergolide—ADRA2A—lymph node—urinary bladder cancer	0.00101	0.00441	CbGeAlD
Pergolide—Somnolence—Etoposide—urinary bladder cancer	0.000392	0.00051	CcSEcCtD
Pergolide—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000392	0.00051	CcSEcCtD
Pergolide—Epistaxis—Methotrexate—urinary bladder cancer	0.000391	0.000509	CcSEcCtD
Pergolide—Vomiting—Thiotepa—urinary bladder cancer	0.000391	0.000508	CcSEcCtD
Pergolide—Pneumonia—Epirubicin—urinary bladder cancer	0.00039	0.000507	CcSEcCtD
Pergolide—Rash—Thiotepa—urinary bladder cancer	0.000388	0.000504	CcSEcCtD
Pergolide—Bronchitis—Doxorubicin—urinary bladder cancer	0.000387	0.000504	CcSEcCtD
Pergolide—Dermatitis—Thiotepa—urinary bladder cancer	0.000387	0.000503	CcSEcCtD
Pergolide—Headache—Thiotepa—urinary bladder cancer	0.000385	0.000501	CcSEcCtD
Pergolide—Decreased appetite—Etoposide—urinary bladder cancer	0.000384	0.000499	CcSEcCtD
Pergolide—Renal failure—Epirubicin—urinary bladder cancer	0.000381	0.000496	CcSEcCtD
Pergolide—Body temperature increased—Cisplatin—urinary bladder cancer	0.000381	0.000495	CcSEcCtD
Pergolide—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.00038	0.000495	CcSEcCtD
Pergolide—Jaundice—Epirubicin—urinary bladder cancer	0.000378	0.000492	CcSEcCtD
Pergolide—Constipation—Etoposide—urinary bladder cancer	0.000378	0.000491	CcSEcCtD
Pergolide—Pain—Etoposide—urinary bladder cancer	0.000378	0.000491	CcSEcCtD
Pergolide—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000377	0.00049	CcSEcCtD
Pergolide—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000377	0.00049	CcSEcCtD
Pergolide—Dysuria—Doxorubicin—urinary bladder cancer	0.000377	0.00049	CcSEcCtD
Pergolide—Hepatitis—Methotrexate—urinary bladder cancer	0.000372	0.000484	CcSEcCtD
Pergolide—Sweating—Epirubicin—urinary bladder cancer	0.000372	0.000484	CcSEcCtD
Pergolide—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000372	0.000484	CcSEcCtD
Pergolide—Asthenia—Gemcitabine—urinary bladder cancer	0.000371	0.000482	CcSEcCtD
Pergolide—Haematuria—Epirubicin—urinary bladder cancer	0.00037	0.000481	CcSEcCtD
Pergolide—Pharyngitis—Methotrexate—urinary bladder cancer	0.000369	0.00048	CcSEcCtD
Pergolide—Weight increased—Doxorubicin—urinary bladder cancer	0.000366	0.000477	CcSEcCtD
Pergolide—Epistaxis—Epirubicin—urinary bladder cancer	0.000366	0.000476	CcSEcCtD
Pergolide—Pruritus—Gemcitabine—urinary bladder cancer	0.000366	0.000476	CcSEcCtD
Pergolide—Nausea—Thiotepa—urinary bladder cancer	0.000365	0.000475	CcSEcCtD
Pergolide—Weight decreased—Doxorubicin—urinary bladder cancer	0.000364	0.000474	CcSEcCtD
Pergolide—Sinusitis—Epirubicin—urinary bladder cancer	0.000364	0.000473	CcSEcCtD
Pergolide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000364	0.000473	CcSEcCtD
Pergolide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000363	0.000472	CcSEcCtD
Pergolide—Pneumonia—Doxorubicin—urinary bladder cancer	0.000361	0.00047	CcSEcCtD
Pergolide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000361	0.000469	CcSEcCtD
Pergolide—Pruritus—Fluorouracil—urinary bladder cancer	0.00036	0.000468	CcSEcCtD
Pergolide—Visual impairment—Methotrexate—urinary bladder cancer	0.000359	0.000466	CcSEcCtD
Pergolide—Bradycardia—Epirubicin—urinary bladder cancer	0.000355	0.000461	CcSEcCtD
Pergolide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000354	0.00046	CcSEcCtD
Pergolide—Renal failure—Doxorubicin—urinary bladder cancer	0.000353	0.000459	CcSEcCtD
Pergolide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000352	0.000458	CcSEcCtD
Pergolide—Jaundice—Doxorubicin—urinary bladder cancer	0.00035	0.000455	CcSEcCtD
Pergolide—Rhinitis—Epirubicin—urinary bladder cancer	0.000349	0.000454	CcSEcCtD
Pergolide—Body temperature increased—Etoposide—urinary bladder cancer	0.000349	0.000454	CcSEcCtD
Pergolide—Abdominal pain—Etoposide—urinary bladder cancer	0.000349	0.000454	CcSEcCtD
Pergolide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000349	0.000454	CcSEcCtD
Pergolide—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000349	0.000454	CcSEcCtD
Pergolide—Hepatitis—Epirubicin—urinary bladder cancer	0.000348	0.000453	CcSEcCtD
Pergolide—Eye disorder—Methotrexate—urinary bladder cancer	0.000348	0.000452	CcSEcCtD
Pergolide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000348	0.000452	CcSEcCtD
Pergolide—Tinnitus—Methotrexate—urinary bladder cancer	0.000347	0.000451	CcSEcCtD
Pergolide—Asthenia—Cisplatin—urinary bladder cancer	0.000346	0.00045	CcSEcCtD
Pergolide—Pharyngitis—Epirubicin—urinary bladder cancer	0.000346	0.00045	CcSEcCtD
Pergolide—Sweating—Doxorubicin—urinary bladder cancer	0.000344	0.000448	CcSEcCtD
Pergolide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000343	0.000446	CcSEcCtD
Pergolide—Haematuria—Doxorubicin—urinary bladder cancer	0.000342	0.000445	CcSEcCtD
Pergolide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000339	0.00044	CcSEcCtD
Pergolide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000337	0.000438	CcSEcCtD
Pergolide—Dizziness—Fluorouracil—urinary bladder cancer	0.000336	0.000437	CcSEcCtD
Pergolide—Visual impairment—Epirubicin—urinary bladder cancer	0.000336	0.000437	CcSEcCtD
Pergolide—Chills—Methotrexate—urinary bladder cancer	0.000334	0.000434	CcSEcCtD
Pergolide—Diarrhoea—Cisplatin—urinary bladder cancer	0.00033	0.000429	CcSEcCtD
Pergolide—Alopecia—Methotrexate—urinary bladder cancer	0.000329	0.000428	CcSEcCtD
Pergolide—Vomiting—Gemcitabine—urinary bladder cancer	0.000329	0.000427	CcSEcCtD
Pergolide—Bradycardia—Doxorubicin—urinary bladder cancer	0.000328	0.000427	CcSEcCtD
Pergolide—Rash—Gemcitabine—urinary bladder cancer	0.000326	0.000424	CcSEcCtD
Pergolide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000326	0.000424	CcSEcCtD
Pergolide—Eye disorder—Epirubicin—urinary bladder cancer	0.000326	0.000423	CcSEcCtD
Pergolide—Tinnitus—Epirubicin—urinary bladder cancer	0.000325	0.000422	CcSEcCtD
Pergolide—Headache—Gemcitabine—urinary bladder cancer	0.000324	0.000421	CcSEcCtD
Pergolide—Vomiting—Fluorouracil—urinary bladder cancer	0.000323	0.00042	CcSEcCtD
Pergolide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000323	0.00042	CcSEcCtD
Pergolide—Hepatitis—Doxorubicin—urinary bladder cancer	0.000322	0.000419	CcSEcCtD
Pergolide—Rash—Fluorouracil—urinary bladder cancer	0.000321	0.000417	CcSEcCtD
Pergolide—Dermatitis—Fluorouracil—urinary bladder cancer	0.00032	0.000416	CcSEcCtD
Pergolide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00032	0.000416	CcSEcCtD
Pergolide—Headache—Fluorouracil—urinary bladder cancer	0.000318	0.000414	CcSEcCtD
Pergolide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000318	0.000413	CcSEcCtD
Pergolide—Dysgeusia—Methotrexate—urinary bladder cancer	0.000317	0.000413	CcSEcCtD
Pergolide—Asthenia—Etoposide—urinary bladder cancer	0.000317	0.000412	CcSEcCtD
Pergolide—Back pain—Methotrexate—urinary bladder cancer	0.000313	0.000408	CcSEcCtD
Pergolide—Chills—Epirubicin—urinary bladder cancer	0.000313	0.000406	CcSEcCtD
Pergolide—Pruritus—Etoposide—urinary bladder cancer	0.000312	0.000406	CcSEcCtD
Pergolide—Arrhythmia—Epirubicin—urinary bladder cancer	0.000311	0.000405	CcSEcCtD
Pergolide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000311	0.000404	CcSEcCtD
Pergolide—Alopecia—Epirubicin—urinary bladder cancer	0.000308	0.0004	CcSEcCtD
Pergolide—Nausea—Gemcitabine—urinary bladder cancer	0.000307	0.000399	CcSEcCtD
Pergolide—Vomiting—Cisplatin—urinary bladder cancer	0.000306	0.000398	CcSEcCtD
Pergolide—Rash—Cisplatin—urinary bladder cancer	0.000304	0.000395	CcSEcCtD
Pergolide—Dermatitis—Cisplatin—urinary bladder cancer	0.000304	0.000395	CcSEcCtD
Pergolide—Diarrhoea—Etoposide—urinary bladder cancer	0.000302	0.000393	CcSEcCtD
Pergolide—Nausea—Fluorouracil—urinary bladder cancer	0.000302	0.000393	CcSEcCtD
Pergolide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000301	0.000392	CcSEcCtD
Pergolide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000301	0.000391	CcSEcCtD
Pergolide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000301	0.000391	CcSEcCtD
Pergolide—Anaemia—Methotrexate—urinary bladder cancer	0.000299	0.000389	CcSEcCtD
Pergolide—Flatulence—Epirubicin—urinary bladder cancer	0.000299	0.000389	CcSEcCtD
Pergolide—Tension—Epirubicin—urinary bladder cancer	0.000298	0.000387	CcSEcCtD
Pergolide—Dysgeusia—Epirubicin—urinary bladder cancer	0.000297	0.000386	CcSEcCtD
Pergolide—Nervousness—Epirubicin—urinary bladder cancer	0.000295	0.000383	CcSEcCtD
Pergolide—Back pain—Epirubicin—urinary bladder cancer	0.000293	0.000381	CcSEcCtD
Pergolide—Malaise—Methotrexate—urinary bladder cancer	0.000292	0.00038	CcSEcCtD
Pergolide—Dizziness—Etoposide—urinary bladder cancer	0.000292	0.00038	CcSEcCtD
Pergolide—Vertigo—Methotrexate—urinary bladder cancer	0.000291	0.000379	CcSEcCtD
Pergolide—Leukopenia—Methotrexate—urinary bladder cancer	0.00029	0.000377	CcSEcCtD
Pergolide—Chills—Doxorubicin—urinary bladder cancer	0.000289	0.000376	CcSEcCtD
Pergolide—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000288	0.000374	CcSEcCtD
Pergolide—Nausea—Cisplatin—urinary bladder cancer	0.000286	0.000372	CcSEcCtD
Pergolide—Alopecia—Doxorubicin—urinary bladder cancer	0.000285	0.00037	CcSEcCtD
Pergolide—Cough—Methotrexate—urinary bladder cancer	0.000283	0.000368	CcSEcCtD
Pergolide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000281	0.000366	CcSEcCtD
Pergolide—Convulsion—Methotrexate—urinary bladder cancer	0.000281	0.000365	CcSEcCtD
Pergolide—Vomiting—Etoposide—urinary bladder cancer	0.000281	0.000365	CcSEcCtD
Pergolide—Anaemia—Epirubicin—urinary bladder cancer	0.00028	0.000364	CcSEcCtD
Pergolide—Agitation—Epirubicin—urinary bladder cancer	0.000279	0.000362	CcSEcCtD
Pergolide—Rash—Etoposide—urinary bladder cancer	0.000278	0.000362	CcSEcCtD
Pergolide—Dermatitis—Etoposide—urinary bladder cancer	0.000278	0.000362	CcSEcCtD
Pergolide—Headache—Etoposide—urinary bladder cancer	0.000277	0.00036	CcSEcCtD
Pergolide—Flatulence—Doxorubicin—urinary bladder cancer	0.000276	0.00036	CcSEcCtD
Pergolide—Myalgia—Methotrexate—urinary bladder cancer	0.000276	0.000359	CcSEcCtD
Pergolide—Arthralgia—Methotrexate—urinary bladder cancer	0.000276	0.000359	CcSEcCtD
Pergolide—Chest pain—Methotrexate—urinary bladder cancer	0.000276	0.000359	CcSEcCtD
Pergolide—Tension—Doxorubicin—urinary bladder cancer	0.000275	0.000358	CcSEcCtD
Pergolide—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000275	0.000357	CcSEcCtD
Pergolide—Malaise—Epirubicin—urinary bladder cancer	0.000273	0.000356	CcSEcCtD
Pergolide—Discomfort—Methotrexate—urinary bladder cancer	0.000273	0.000354	CcSEcCtD
Pergolide—Nervousness—Doxorubicin—urinary bladder cancer	0.000273	0.000354	CcSEcCtD
Pergolide—Vertigo—Epirubicin—urinary bladder cancer	0.000272	0.000354	CcSEcCtD
Pergolide—Syncope—Epirubicin—urinary bladder cancer	0.000272	0.000354	CcSEcCtD
Pergolide—Leukopenia—Epirubicin—urinary bladder cancer	0.000271	0.000353	CcSEcCtD
Pergolide—Back pain—Doxorubicin—urinary bladder cancer	0.000271	0.000353	CcSEcCtD
Pergolide—Palpitations—Epirubicin—urinary bladder cancer	0.000268	0.000348	CcSEcCtD
Pergolide—Confusional state—Methotrexate—urinary bladder cancer	0.000267	0.000347	CcSEcCtD
Pergolide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000267	0.000347	CcSEcCtD
Pergolide—Cough—Epirubicin—urinary bladder cancer	0.000265	0.000344	CcSEcCtD
Pergolide—Convulsion—Epirubicin—urinary bladder cancer	0.000263	0.000342	CcSEcCtD
Pergolide—Infection—Methotrexate—urinary bladder cancer	0.000263	0.000342	CcSEcCtD
Pergolide—Nausea—Etoposide—urinary bladder cancer	0.000262	0.000341	CcSEcCtD
Pergolide—Hypertension—Epirubicin—urinary bladder cancer	0.000262	0.00034	CcSEcCtD
Pergolide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00026	0.000339	CcSEcCtD
Pergolide—Anaemia—Doxorubicin—urinary bladder cancer	0.000259	0.000337	CcSEcCtD
Pergolide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000259	0.000337	CcSEcCtD
Pergolide—Arthralgia—Epirubicin—urinary bladder cancer	0.000258	0.000336	CcSEcCtD
Pergolide—Chest pain—Epirubicin—urinary bladder cancer	0.000258	0.000336	CcSEcCtD
Pergolide—Myalgia—Epirubicin—urinary bladder cancer	0.000258	0.000336	CcSEcCtD
Pergolide—Agitation—Doxorubicin—urinary bladder cancer	0.000258	0.000335	CcSEcCtD
Pergolide—Anxiety—Epirubicin—urinary bladder cancer	0.000257	0.000335	CcSEcCtD
Pergolide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000256	0.000332	CcSEcCtD
Pergolide—Discomfort—Epirubicin—urinary bladder cancer	0.000255	0.000332	CcSEcCtD
Pergolide—Malaise—Doxorubicin—urinary bladder cancer	0.000253	0.000329	CcSEcCtD
Pergolide—Dry mouth—Epirubicin—urinary bladder cancer	0.000252	0.000328	CcSEcCtD
Pergolide—Vertigo—Doxorubicin—urinary bladder cancer	0.000252	0.000328	CcSEcCtD
Pergolide—Anorexia—Methotrexate—urinary bladder cancer	0.000252	0.000328	CcSEcCtD
Pergolide—Syncope—Doxorubicin—urinary bladder cancer	0.000252	0.000327	CcSEcCtD
Pergolide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000251	0.000327	CcSEcCtD
Pergolide—Confusional state—Epirubicin—urinary bladder cancer	0.00025	0.000324	CcSEcCtD
Pergolide—Palpitations—Doxorubicin—urinary bladder cancer	0.000248	0.000322	CcSEcCtD
Pergolide—Oedema—Epirubicin—urinary bladder cancer	0.000247	0.000322	CcSEcCtD
Pergolide—Hypotension—Methotrexate—urinary bladder cancer	0.000247	0.000321	CcSEcCtD
Pergolide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000247	0.000321	CcSEcCtD
Pergolide—Infection—Epirubicin—urinary bladder cancer	0.000246	0.00032	CcSEcCtD
Pergolide—Cough—Doxorubicin—urinary bladder cancer	0.000245	0.000318	CcSEcCtD
Pergolide—Shock—Epirubicin—urinary bladder cancer	0.000243	0.000317	CcSEcCtD
Pergolide—Convulsion—Doxorubicin—urinary bladder cancer	0.000243	0.000316	CcSEcCtD
Pergolide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000242	0.000315	CcSEcCtD
Pergolide—Hypertension—Doxorubicin—urinary bladder cancer	0.000242	0.000315	CcSEcCtD
Pergolide—Tachycardia—Epirubicin—urinary bladder cancer	0.000242	0.000314	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000241	0.000313	CcSEcCtD
Pergolide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000239	0.000311	CcSEcCtD
Pergolide—Insomnia—Methotrexate—urinary bladder cancer	0.000239	0.000311	CcSEcCtD
Pergolide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000239	0.000311	CcSEcCtD
Pergolide—Myalgia—Doxorubicin—urinary bladder cancer	0.000239	0.000311	CcSEcCtD
Pergolide—Chest pain—Doxorubicin—urinary bladder cancer	0.000239	0.000311	CcSEcCtD
Pergolide—Anxiety—Doxorubicin—urinary bladder cancer	0.000238	0.00031	CcSEcCtD
Pergolide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000237	0.000309	CcSEcCtD
Pergolide—Discomfort—Doxorubicin—urinary bladder cancer	0.000236	0.000307	CcSEcCtD
Pergolide—Anorexia—Epirubicin—urinary bladder cancer	0.000236	0.000307	CcSEcCtD
Pergolide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000236	0.000307	CcSEcCtD
Pergolide—Somnolence—Methotrexate—urinary bladder cancer	0.000235	0.000306	CcSEcCtD
Pergolide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000234	0.000304	CcSEcCtD
Pergolide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000233	0.000303	CcSEcCtD
Pergolide—Hypotension—Epirubicin—urinary bladder cancer	0.000231	0.000301	CcSEcCtD
Pergolide—Confusional state—Doxorubicin—urinary bladder cancer	0.000231	0.0003	CcSEcCtD
Pergolide—Decreased appetite—Methotrexate—urinary bladder cancer	0.00023	0.000299	CcSEcCtD
Pergolide—Oedema—Doxorubicin—urinary bladder cancer	0.000229	0.000298	CcSEcCtD
Pergolide—Infection—Doxorubicin—urinary bladder cancer	0.000227	0.000296	CcSEcCtD
Pergolide—Pain—Methotrexate—urinary bladder cancer	0.000226	0.000294	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000225	0.000293	CcSEcCtD
Pergolide—Shock—Doxorubicin—urinary bladder cancer	0.000225	0.000293	CcSEcCtD
Pergolide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000224	0.000292	CcSEcCtD
Pergolide—Insomnia—Epirubicin—urinary bladder cancer	0.000224	0.000291	CcSEcCtD
Pergolide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000223	0.000291	CcSEcCtD
Pergolide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000222	0.000289	CcSEcCtD
Pergolide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000221	0.000288	CcSEcCtD
Pergolide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000221	0.000287	CcSEcCtD
Pergolide—Somnolence—Epirubicin—urinary bladder cancer	0.00022	0.000286	CcSEcCtD
Pergolide—Anorexia—Doxorubicin—urinary bladder cancer	0.000218	0.000284	CcSEcCtD
Pergolide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000218	0.000283	CcSEcCtD
Pergolide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000218	0.000283	CcSEcCtD
Pergolide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000216	0.000281	CcSEcCtD
Pergolide—Decreased appetite—Epirubicin—urinary bladder cancer	0.000215	0.00028	CcSEcCtD
Pergolide—Hypotension—Doxorubicin—urinary bladder cancer	0.000214	0.000278	CcSEcCtD
Pergolide—Pain—Epirubicin—urinary bladder cancer	0.000212	0.000275	CcSEcCtD
Pergolide—Constipation—Epirubicin—urinary bladder cancer	0.000212	0.000275	CcSEcCtD
Pergolide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000209	0.000272	CcSEcCtD
Pergolide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000209	0.000272	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000209	0.000271	CcSEcCtD
Pergolide—Insomnia—Doxorubicin—urinary bladder cancer	0.000207	0.000269	CcSEcCtD
Pergolide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000206	0.000267	CcSEcCtD
Pergolide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000204	0.000265	CcSEcCtD
Pergolide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000204	0.000265	CcSEcCtD
Pergolide—Somnolence—Doxorubicin—urinary bladder cancer	0.000204	0.000265	CcSEcCtD
Pergolide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000202	0.000263	CcSEcCtD
Pergolide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000202	0.000262	CcSEcCtD
Pergolide—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000199	0.000259	CcSEcCtD
Pergolide—Pain—Doxorubicin—urinary bladder cancer	0.000196	0.000255	CcSEcCtD
Pergolide—Constipation—Doxorubicin—urinary bladder cancer	0.000196	0.000255	CcSEcCtD
Pergolide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000196	0.000254	CcSEcCtD
Pergolide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000196	0.000254	CcSEcCtD
Pergolide—Asthenia—Methotrexate—urinary bladder cancer	0.00019	0.000247	CcSEcCtD
Pergolide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000189	0.000245	CcSEcCtD
Pergolide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000187	0.000243	CcSEcCtD
Pergolide—Pruritus—Methotrexate—urinary bladder cancer	0.000187	0.000243	CcSEcCtD
Pergolide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000181	0.000235	CcSEcCtD
Pergolide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000181	0.000235	CcSEcCtD
Pergolide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000181	0.000235	CcSEcCtD
Pergolide—Asthenia—Epirubicin—urinary bladder cancer	0.000178	0.000231	CcSEcCtD
Pergolide—Pruritus—Epirubicin—urinary bladder cancer	0.000175	0.000228	CcSEcCtD
Pergolide—Dizziness—Methotrexate—urinary bladder cancer	0.000175	0.000227	CcSEcCtD
Pergolide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000169	0.00022	CcSEcCtD
Pergolide—Vomiting—Methotrexate—urinary bladder cancer	0.000168	0.000219	CcSEcCtD
Pergolide—Rash—Methotrexate—urinary bladder cancer	0.000167	0.000217	CcSEcCtD
Pergolide—Dermatitis—Methotrexate—urinary bladder cancer	0.000167	0.000217	CcSEcCtD
Pergolide—Headache—Methotrexate—urinary bladder cancer	0.000166	0.000215	CcSEcCtD
Pergolide—Asthenia—Doxorubicin—urinary bladder cancer	0.000164	0.000214	CcSEcCtD
Pergolide—Dizziness—Epirubicin—urinary bladder cancer	0.000164	0.000213	CcSEcCtD
Pergolide—Pruritus—Doxorubicin—urinary bladder cancer	0.000162	0.000211	CcSEcCtD
Pergolide—Vomiting—Epirubicin—urinary bladder cancer	0.000157	0.000205	CcSEcCtD
Pergolide—Nausea—Methotrexate—urinary bladder cancer	0.000157	0.000204	CcSEcCtD
Pergolide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000157	0.000204	CcSEcCtD
Pergolide—Rash—Epirubicin—urinary bladder cancer	0.000156	0.000203	CcSEcCtD
Pergolide—Dermatitis—Epirubicin—urinary bladder cancer	0.000156	0.000203	CcSEcCtD
Pergolide—Headache—Epirubicin—urinary bladder cancer	0.000155	0.000202	CcSEcCtD
Pergolide—Dizziness—Doxorubicin—urinary bladder cancer	0.000151	0.000197	CcSEcCtD
Pergolide—Nausea—Epirubicin—urinary bladder cancer	0.000147	0.000191	CcSEcCtD
Pergolide—Vomiting—Doxorubicin—urinary bladder cancer	0.000146	0.000189	CcSEcCtD
Pergolide—Rash—Doxorubicin—urinary bladder cancer	0.000144	0.000188	CcSEcCtD
Pergolide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000144	0.000188	CcSEcCtD
Pergolide—Headache—Doxorubicin—urinary bladder cancer	0.000143	0.000187	CcSEcCtD
Pergolide—Nausea—Doxorubicin—urinary bladder cancer	0.000136	0.000177	CcSEcCtD
Pergolide—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	4.62e-07	0.000224	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	4.61e-07	0.000223	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL2—urinary bladder cancer	4.61e-07	0.000223	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	4.61e-07	0.000223	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	4.6e-07	0.000223	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—EP300—urinary bladder cancer	4.59e-07	0.000222	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	4.58e-07	0.000222	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	4.57e-07	0.000221	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL2—urinary bladder cancer	4.54e-07	0.00022	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL2—urinary bladder cancer	4.54e-07	0.00022	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	4.54e-07	0.00022	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	4.53e-07	0.000219	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	4.52e-07	0.000219	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	4.51e-07	0.000218	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	4.5e-07	0.000218	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	4.5e-07	0.000218	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—CCND1—urinary bladder cancer	4.49e-07	0.000217	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—SRC—urinary bladder cancer	4.46e-07	0.000216	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	4.45e-07	0.000216	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—TP53—urinary bladder cancer	4.45e-07	0.000216	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.45e-07	0.000215	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—CCND1—urinary bladder cancer	4.43e-07	0.000215	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	4.43e-07	0.000215	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	4.43e-07	0.000215	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	4.41e-07	0.000214	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	4.38e-07	0.000212	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	4.37e-07	0.000212	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.36e-07	0.000211	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	4.36e-07	0.000211	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	4.36e-07	0.000211	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	4.35e-07	0.000211	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.34e-07	0.00021	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	4.34e-07	0.00021	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	4.33e-07	0.00021	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PTEN—urinary bladder cancer	4.31e-07	0.000209	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	4.3e-07	0.000208	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	4.3e-07	0.000208	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	4.29e-07	0.000208	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	4.29e-07	0.000208	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	4.29e-07	0.000208	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	4.28e-07	0.000207	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	4.28e-07	0.000207	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	4.27e-07	0.000207	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	4.26e-07	0.000206	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—HRAS—urinary bladder cancer	4.26e-07	0.000206	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	4.25e-07	0.000206	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	4.23e-07	0.000205	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	4.18e-07	0.000203	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	4.16e-07	0.000202	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	4.15e-07	0.000201	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	4.14e-07	0.000201	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	4.14e-07	0.000201	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—EP300—urinary bladder cancer	4.13e-07	0.0002	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	4.12e-07	0.0002	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	4.12e-07	0.000199	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—EP300—urinary bladder cancer	4.11e-07	0.000199	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	4.1e-07	0.000199	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	4.1e-07	0.000199	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	4.1e-07	0.000199	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	4.1e-07	0.000198	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	4.1e-07	0.000198	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	4.08e-07	0.000198	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	4.08e-07	0.000197	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EP300—urinary bladder cancer	4.08e-07	0.000197	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	4.07e-07	0.000197	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	4.06e-07	0.000197	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	4.05e-07	0.000196	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	4.03e-07	0.000195	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—SRC—urinary bladder cancer	4.02e-07	0.000195	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	4.02e-07	0.000195	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	4.01e-07	0.000194	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—MYC—urinary bladder cancer	4e-07	0.000194	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	4e-07	0.000194	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	3.99e-07	0.000193	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	3.98e-07	0.000193	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	3.98e-07	0.000193	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	3.97e-07	0.000192	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—SRC—urinary bladder cancer	3.97e-07	0.000192	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	3.96e-07	0.000192	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.96e-07	0.000192	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	3.95e-07	0.000191	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	3.94e-07	0.000191	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	3.92e-07	0.00019	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	3.91e-07	0.00019	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	3.88e-07	0.000188	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.87e-07	0.000187	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	3.86e-07	0.000187	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	3.86e-07	0.000187	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	3.84e-07	0.000186	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	3.84e-07	0.000186	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	3.84e-07	0.000186	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	3.83e-07	0.000186	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	3.82e-07	0.000185	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	3.81e-07	0.000184	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	3.78e-07	0.000183	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	3.77e-07	0.000183	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	3.76e-07	0.000182	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	3.75e-07	0.000182	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	3.74e-07	0.000181	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	3.74e-07	0.000181	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.74e-07	0.000181	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	3.73e-07	0.000181	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	3.73e-07	0.00018	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	3.72e-07	0.00018	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	3.71e-07	0.00018	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	3.71e-07	0.00018	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	3.7e-07	0.000179	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	3.7e-07	0.000179	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	3.68e-07	0.000178	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	3.68e-07	0.000178	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	3.64e-07	0.000176	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	3.63e-07	0.000176	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	3.62e-07	0.000175	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	3.61e-07	0.000175	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	3.61e-07	0.000175	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MYC—urinary bladder cancer	3.6e-07	0.000174	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.58e-07	0.000173	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	3.58e-07	0.000173	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	3.57e-07	0.000173	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.56e-07	0.000172	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.56e-07	0.000172	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	3.55e-07	0.000172	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MYC—urinary bladder cancer	3.55e-07	0.000172	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	3.55e-07	0.000172	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	3.55e-07	0.000172	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	3.54e-07	0.000171	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	3.53e-07	0.000171	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	3.52e-07	0.000171	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	3.51e-07	0.00017	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTEN—urinary bladder cancer	3.5e-07	0.00017	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	3.48e-07	0.000169	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL2—urinary bladder cancer	3.48e-07	0.000168	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	3.48e-07	0.000168	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	3.48e-07	0.000168	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	3.46e-07	0.000167	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	3.44e-07	0.000167	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	3.44e-07	0.000167	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	3.43e-07	0.000166	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	3.42e-07	0.000166	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	3.41e-07	0.000165	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	3.39e-07	0.000164	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	3.38e-07	0.000164	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	3.35e-07	0.000162	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	3.34e-07	0.000162	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—EP300—urinary bladder cancer	3.34e-07	0.000162	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	3.34e-07	0.000162	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	3.34e-07	0.000162	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	3.33e-07	0.000161	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.33e-07	0.000161	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.3e-07	0.00016	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	3.29e-07	0.000159	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	3.29e-07	0.000159	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—urinary bladder cancer	3.29e-07	0.000159	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	3.28e-07	0.000159	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	3.28e-07	0.000159	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	3.28e-07	0.000159	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	3.27e-07	0.000158	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	3.27e-07	0.000158	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	3.26e-07	0.000158	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	3.26e-07	0.000158	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	3.24e-07	0.000157	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	3.24e-07	0.000157	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.23e-07	0.000156	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	3.22e-07	0.000156	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	3.21e-07	0.000155	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.2e-07	0.000155	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	3.19e-07	0.000155	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	3.17e-07	0.000154	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.16e-07	0.000153	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	3.15e-07	0.000153	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	3.14e-07	0.000152	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	3.14e-07	0.000152	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	3.14e-07	0.000152	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EP300—urinary bladder cancer	3.12e-07	0.000151	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	3.11e-07	0.000151	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	3.1e-07	0.00015	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	3.08e-07	0.000149	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.07e-07	0.000149	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	3.07e-07	0.000149	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.04e-07	0.000147	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.04e-07	0.000147	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	3.03e-07	0.000147	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—SRC—urinary bladder cancer	3.03e-07	0.000147	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	3.03e-07	0.000147	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	3.01e-07	0.000146	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	3.01e-07	0.000146	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	3e-07	0.000145	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	3e-07	0.000145	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	2.99e-07	0.000145	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	2.96e-07	0.000144	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—urinary bladder cancer	2.96e-07	0.000143	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	2.95e-07	0.000143	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	2.95e-07	0.000143	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.94e-07	0.000142	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	2.93e-07	0.000142	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	2.93e-07	0.000142	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	2.92e-07	0.000142	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	2.92e-07	0.000141	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—urinary bladder cancer	2.92e-07	0.000141	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.91e-07	0.000141	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	2.88e-07	0.00014	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	2.86e-07	0.000139	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.85e-07	0.000138	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	2.85e-07	0.000138	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	2.83e-07	0.000137	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	2.79e-07	0.000135	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	2.79e-07	0.000135	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	2.79e-07	0.000135	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	2.77e-07	0.000134	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	2.73e-07	0.000132	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—urinary bladder cancer	2.72e-07	0.000132	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	2.72e-07	0.000132	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.68e-07	0.00013	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	2.68e-07	0.00013	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	2.66e-07	0.000129	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	2.63e-07	0.000128	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	2.62e-07	0.000127	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.62e-07	0.000127	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	2.62e-07	0.000127	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	2.56e-07	0.000124	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	2.54e-07	0.000123	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	2.53e-07	0.000123	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	2.52e-07	0.000122	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	2.51e-07	0.000122	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	2.47e-07	0.00012	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	2.46e-07	0.000119	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	2.43e-07	0.000118	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	2.43e-07	0.000118	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	2.42e-07	0.000117	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	2.42e-07	0.000117	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	2.42e-07	0.000117	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	2.38e-07	0.000115	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	2.35e-07	0.000114	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	2.32e-07	0.000112	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.28e-07	0.000111	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.25e-07	0.000109	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—urinary bladder cancer	2.23e-07	0.000108	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	2.2e-07	0.000106	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.18e-07	0.000105	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.18e-07	0.000105	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	2.15e-07	0.000104	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	2.14e-07	0.000103	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	2.1e-07	0.000102	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.09e-07	0.000101	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	2.06e-07	9.96e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	2e-07	9.68e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.91e-07	9.26e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.71e-07	8.29e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.49e-07	7.23e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.42e-07	6.89e-05	CbGpPWpGaD
